5 active not recruiting, 4 completed, 1 terminated. 7 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Active not recruiting 3, Completed 3, Terminated 1 |
| Phase 1 | 2 | Active not recruiting 1, Completed 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Stage III Ureter Cancer AJCC v8: new trials by email Literature Review of Stage III Ureter Cancer AJCC v8 trials Research Report on Stage III Ureter Cancer AJCC v8
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study Avelumab, Biospecimen Collection, Bone Scan - Advanced Bladder Urothelial Carcinoma, Advanced Renal Pelvis Urothelial Carcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 654 | 2022-06-03 | 2026-10-01 |
| Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma Ipilimumab, Nivolumab, Tocilizumab - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 35 | 2021-09-23 | 2026-09-16 |
| ARID1A and/or KDM6A Mutation and CXCL13 Expression Diagnostic Laboratory Biomarker Analysis, Nivolumab, Relatlimab - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 6 | 2021-09-21 | 2026-10-06 |
| Gemcitabine for the Prevention of Intravesical Recurrence of Urothelial Cancer in Patients With Upper Urinary Tract Urothelial Cancer Undergoing Radical Nephroureterectomy, GEMINI Study Gemcitabine Hydrochloride - Stage 0a Renal Pelvis and Ureter Cancer AJCC v8, Stage 0a Renal Pelvis Cancer AJCC v8 | Phase 2 | Terminated | Mayo Clinic | 25 | 2020-06-05 | 2023-08-08 |
| Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma Atezolizumab, Biopsy, Biospecimen Collection - Advanced Bladder Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 47 | 2019-06-05 | 2024-07-26 |
| Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer Avelumab, Cisplatin, Fluorouracil - Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Stage II Bladder Cancer AJCC v8 | Phase 2 | Completed | Mayo Clinic | 2 | 2018-09-19 | 2023-01-06 |
| Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies Abexinostat, Pembrolizumab - Stage III Cutaneous Melanoma, Stage IV Cutaneous Melanoma | Phase 1 | Completed | Rahul Aggarwal | 35 | 2018-08-20 | 2024-03-22 |
| Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer Atezolizumab, Biopsy Procedure, Biospecimen Collection - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 72 | 2018-07-20 | 2026-07-31 |
| Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors Biopsy Procedure, Biospecimen Collection, Cabozantinib S-malate - Bladder Small Cell Neuroendocrine Carcinoma, Bladder Squamous Cell Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 152 | 2015-07-22 | 2026-10-15 |
| Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer Erlotinib Hydrochloride - Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 34 | 2008-06-10 | 2020-09-10 |
Ureteral Neoplasms (10) · Urethral Neoplasms (8) · Urinary Bladder Neoplasms (8) · Carcinoma, Transitional Cell (3) · Carcinoma, Non-Small-Cell Lung (2) · Lung Neoplasms (2) · Melanoma (2) · Carcinoma, Renal Cell (1) · Neoplasm Metastasis (1) · Penile Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1) · Urogenital Neoplasms (1)
Female Urogenital Diseases (10) · Female Urogenital Diseases and Pregnancy Complications (10) · Male Urogenital Diseases (10) · Neoplasms (10) · Neoplasms by Site (10) · Ureteral Diseases (10) · Urogenital Diseases (10) · Urologic Diseases (10) · Urologic Neoplasms (10) · Urogenital Neoplasms (9) · Urethral Diseases (8) · Urinary Bladder Diseases (8) · Neoplasms by Histologic Type (5) · Carcinoma (4) · Neoplasms, Glandular and Epithelial (4)
Specimen Handling (4) · Biopsy (3) · Magnetic Resonance Spectroscopy (3) · Nivolumab (3) · CTLA-4 Antigen (2) · Ipilimumab (2) · atezolizumab (2) · avelumab (2) · cabozantinib (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · Cisplatin (1) · Contrast Media (1) · Disulfides (1) · Erlotinib Hydrochloride (1) · Fluorouracil (1)
National Cancer Institute (NCI) (4) · M.D. Anderson Cancer Center (3) · Mayo Clinic (2) · Rahul Aggarwal (1)
United States (10) · Canada (1)
Andrea B Apolo (1) · Anishka A D'Souza (1) · Arlene Siefker-Radtke (1) · Evan Y Yu (1) · Parminder Singh (1) · Rahul Aggarwal, MD (1) · Rodabe Amaria, MD (1) · Sangeeta Goswami (1) · Shilpa Gupta (1) · Stephen A Boorjian (1)
PMID 32915679, PMID 35031545, PMID 35537412, PMID 37328287, PMID 38954785
UM1CA186717 (2), P30CA015704 (1), P30CA016672 (1), U01CA154967 (1), U10CA180821 (1), UM1CA186712 (1), UM1CA186716 (1), ZIABC011078 (1)